Breadcrumb

[A17-08] Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

Overview

Overview

Commission: Commission awarded on 2017-03-01 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 446 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A17-31] Secukinumab (plaque psoriasis) - Addendum to Commission A17-08
Status: Commission completed

[A15-53] Secukinumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A15-20] Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2017-06-01 Extract of dossier assessment 446 kBPDFdownload file
2017-06-01 Dossier assessment (German version) 603 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close